Transparency of payments and transfers of value
Medicines Australia is a strong advocate for transparency of payments and other ‘transfers of value’ provided by the Australian medicines industry to health consumer organisations and healthcare professionals. The purpose of disclosure of payments and other activities is to demonstrate our ongoing commitment to this endeavour. It is our hope that this disclosure will help the general public to better understand the nature and extent of programs we support in the interest of increasing quality use of medicines, advancing patient care and supporting our local communities.
For this reason, and to ensure continued public confidence in these relationships, the Code of Conduct includes requirements for reporting of payments and benefits to healthcare professionals (e.g. speaker fees, consultant fees, and advisory board member fees) and greater disclosure of the nature of our relationships with health consumer organisations.
As part of the current Code of Conduct Review, the Code Review Panel is investigating options developed by the Transparency Working Group for increased transparency about payments and transfers of value to healthcare professionals for potential inclusion into Edition 18 of the Code of Conduct. The Code Review commenced in July 2013 and will conclude in June 2014, with Edition 18 becoming effective in January 2015.
Further information about the Code Review is available from the Review webpage.
Medicines Australia Code of Conduct
All of the actitives reported by Medicines Australia member companies are subject to the Medicines Australia Code of Conduct. The Code of Conduct is authorised by the ACCC and is updated regularly. It sets the standard for the ethical marketing and promotion of medicines.
Under the Code, the provision of gifts to doctors is banned. Entertainment is banned. The provision of lavish hospitality is banned.
Breaching the Code of Conduct
Where a breach of the Code of Conduct is suspected, a complaint can be lodged with the Code of Conduct Committee, an independent body chaired by a trade practices lawyer.
Companies found to have breached the Code of Conduct can be fined up to $300,000.
Medicines Australia invites scrutiny of these activities. We encourage people to lodge a complaint with the independent Code of Conduct Committee where they think company behaviour may be inappropriate.
Click on the links below for further information:
- Medicines Australia Code of Conduct (Edition 17)
- Advisory Board Reports
- Educational Event Reports
- Health Consider Organisation Support Reports
- Healthcare Professional Consultant Reports
- Frequently Asked Questions (FAQs)
- Useful links